Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE was delisted on the 3rd of May, 2023.
76 hedge funds and large institutions have $239M invested in Jounce Therapeutics, Inc. Common Stock in 2017 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 38 increasing their positions, 10 reducing their positions, and 9 closing their positions.
280% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 10
44% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 9
23% more capital invested
Capital invested by funds: $195M → $239M (+$44.2M)
6% more funds holding
Funds holding: 72 → 76 (+4)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$14.6M |
| 2 |
BlackRock
New York
|
+$5.17M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.58M |
| 4 |
CC
Casdin Capital
New York
|
+$3.39M |
| 5 |
FI
Fosun International
Hong Kong,
China
|
+$2.73M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.89M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$7.91M |
| 3 |
DM
Deerfield Management
New York
|
-$3.48M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$2.58M |
| 5 |
Millennium Management
New York
|
-$2.05M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DM
76
Deerfield Management
New York
| – | -$3.48M | -247,872 | Closed |
|
77
Prudential Financial
Newark,
New Jersey
| – | -$958K | -68,280 | Closed |
|
|
UOTTAIMCU
78
University of Texas/Texas AM Investment Management Co (UTIMCO)
Austin,
Texas
| – | -$428K | -30,488 | Closed |
|
|
HHC
79
Hutchin Hill Capital
New York
| – | -$422K | -30,100 | Closed |
|
80
D.E. Shaw & Co
New York
| – | -$271K | -19,323 | Closed |
|
|
MIM
81
Monashee Investment Management
Boston,
Massachusetts
| – | -$249K | -17,773 | Closed |
|
82
Citadel Advisors
Miami,
Florida
| – | -$200K | -14,245 | Closed |
|
|
PAM
83
Panagora Asset Management
Boston,
Massachusetts
| – | -$8K | -581 | Closed |
|
|
LA
84
Legacy Advisors
Plymouth Meeting,
Pennsylvania
| – | -$7K | -500 | Closed |
|
85
SEI Investments
Oaks,
Pennsylvania
| – | +$438 | +31 | New |
|
JNCE Hedge Fund Activity: Q3 2017 in Review
76 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q3 2017, worth a combined $239M — up 23% from $195M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new JNCE positions and 9 closed out — a net gain of 4 holders — while 38 added to existing stakes and 10 trimmed.
The largest buyer was PFM Health Sciences, adding an estimated $14.6M. The largest seller was Fidelity Investments, cutting an estimated $9.89M.
- 76 institutional investors held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q3 2017, up from 72 in Q2 2017.
- Funds reported $239M of Jounce Therapeutics, Inc. Common Stock stock for Q3 2017, up 23% quarter-over-quarter.
- 13 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q3 2017 and 9 closed out, a net change of +4 holders.
- The largest Jounce Therapeutics, Inc. Common Stock buyer in Q3 2017 was PFM Health Sciences, an estimated $14.6M added.
- The largest Jounce Therapeutics, Inc. Common Stock seller in Q3 2017 was Fidelity Investments, an estimated $9.89M sold.
Based on aggregated 13F filings for Q3 2017.